A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients
A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
Inclusion Criteria:
Exclusion Criteria:
Jarom¿¿, Czechia
Bia¿ystok, Poland
Bystra ¿l¿ska, Poland
Ch¿ciny, Poland
Cz¿stochowa, Poland
Gorzów Wlkp, Poland
I¿awa, Poland
Otowck, Poland
Wo¿omin, Poland
¿om¿a, Poland
¿ód¿, Poland
Witbank, Gauteng, South Africa
Lyttelton Manor, South Africa